{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:08:57Z","timestamp":1758931737824,"version":"3.44.0"},"reference-count":30,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Juvenile idiopathic arthritis (JIA) presents ongoing treatment challenges despite advances in treatment over the last few years. This review presents that recent studies highlight the potential of Janus kinase inhibitors (JAKi) to significantly reduce disease activity. However, concerns about long-term safety, including cardiovascular risks and malignancy, underscore the need for more research. While JAKi offers a promising therapeutic avenue in pediatric rheumatology, the long-term safety profile requires further investigation to assert its place in standard treatment guidelines.<\/jats:p>","DOI":"10.61409\/v09240622","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T10:46:28Z","timestamp":1755254788000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis"],"prefix":"10.61409","author":[{"given":"Rasmus","family":"Saul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troels","family":"Herlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Glerup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Martini A, Lovell DJ, Albani S, et al. Juvenile idiopathic arthritis. Nature Reviews Disease Primers. 2022;8(1):5. https:\/\/doi.org\/10.1038\/s41572-021-00332-8","DOI":"10.1038\/s41572-021-00332-8"},{"key":"ref1","unstructured":"Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390-2"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Glerup M, Rypdal V, Arnstad ED, et al. Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic juvenile idiopathic arthritis cohort. Arthritis Care Res (Hoboken). 2020;72(4):507-16. https:\/\/doi.org\/10.1002\/acr.23853","DOI":"10.1002\/acr.23853"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition. J Allergy Clin Immunol. 2021;148(4):911-25. https:\/\/doi.org\/10.1016\/j.jaci.2021.08.004","DOI":"10.1016\/j.jaci.2021.08.004"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Verweyen EL, Schulert GS. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA). Rheumatology (Oxford). 2022;61(3):926-35. https:\/\/doi.org\/10.1093\/rheumatology\/keab673","DOI":"10.1093\/rheumatology\/keab673"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Glerup M, Kessel C, Foell D, et al. Inflammatory biomarkers predicting long-term remission and active disease in juvenile idiopathic arthritis: a population-based study of the Nordic JIA cohort. RMD Open. 2024;10(3):e004317. https:\/\/doi.org\/10.1136\/rmdopen-2024-004317","DOI":"10.1136\/rmdopen-2024-004317"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Schmidt T, Dahlberg A, Berthold E, et al. Synovial monocytes contribute to chronic inflammation in childhood-onset arthritis via IL-6\/STAT signalling and cell-cell interactions. Front Immunol. 2023;14:1190018. https:\/\/doi.org\/10.3389\/fimmu.2023.1190018","DOI":"10.3389\/fimmu.2023.1190018"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Melki I, Fr\u00e9mond ML. JAK inhibition in juvenile idiopathic arthritis (JIA): better understanding of a promising therapy for refractory cases. J Clin Med. 2023;12(14). https:\/\/doi.org\/10.3390\/jcm12144695","DOI":"10.3390\/jcm12144695"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Rahman MM, Laila K, Rahman SA. Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: a study from Bangladesh. Int J Rheum Dis. 2022;25(6):678-84. https:\/\/doi.org\/10.1111\/1756-185X.14324","DOI":"10.1111\/1756-185X.14324"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ruperto N, Brunner HI, Synoverska O, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):1984-96. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1","DOI":"10.1016\/S0140-6736(21)01255-1"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Ramanan AV, Quartier P, Okamoto N, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555-70. https:\/\/doi.org\/10.1016\/S0140-6736(23)00921-2","DOI":"10.1016\/S0140-6736(23)00921-2"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Gillard L, Pouchot J, Cohen-Aubart F, et al. JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Rheumatology. 2022;62(4):1594-1604. https:\/\/doi.org\/10.1093\/rheumatology\/keac440","DOI":"10.1093\/rheumatology\/keac440"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Bader-Meunier B, Hadchouel A, Berteloot L, et al. Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report. Ann Rheum Dis. 2022;81(2):e20. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216983","DOI":"10.1136\/annrheumdis-2020-216983"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Macaraeg M, Schulert GS. Complications of complications: diagnosis and treatment of recurrent macrophage activation syndrome in a patient with well-controlled systemic juvenile idiopathic arthritis. RMD Open. 2023;9(1):e002611. https:\/\/doi.org\/10.1136\/rmdopen-2022-002611","DOI":"10.1136\/rmdopen-2022-002611"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637-46. https:\/\/doi.org\/10.1056\/NEJMoa1614160","DOI":"10.1056\/NEJMoa1614160"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Su Y, Tao T, Liu X, Su W. JAK-STAT signaling pathway in non-infectious uveitis. Biochem Pharmacol. 2022;204:115236. https:\/\/doi.org\/10.1016\/j.bcp.2022.115236","DOI":"10.1016\/j.bcp.2022.115236"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39(3):847-51. https:\/\/doi.org\/10.1007\/s10067-019-04875-w","DOI":"10.1007\/s10067-019-04875-w"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27(8):1232-4. https:\/\/doi.org\/10.1080\/09273948.2019.1605453","DOI":"10.1080\/09273948.2019.1605453"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Baquet-Walscheid K, Heinz C, Rath T, et al. Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflamm. 2023;31(5):1079-80. https:\/\/doi.org\/10.1080\/09273948.2022.2069128","DOI":"10.1080\/09273948.2022.2069128"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Alghamdi MA, Mulla J, Saheb Sharif-Askari N, et al. A novel biallelic STING1 gene variant causing SAVI in two siblings. Front Immunol. 2020;11:599564. https:\/\/doi.org\/10.3389\/fimmu.2020.599564","DOI":"10.3389\/fimmu.2020.599564"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Solignac M, Cabrera N, Fouillet-Desjonqueres M, et al. JAK inhibitors in refractory juvenile rheumatic diseases: efficacy, tolerance and type-I interferon profiling, a single center retrospective study. J Autoimmun. 2024;147:103248. https:\/\/doi.org\/10.1016\/j.jaut.2024.103248","DOI":"10.1016\/j.jaut.2024.103248"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Aeschlimann FA, Fr\u00e9mond ML, Duffy D, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80. https:\/\/doi.org\/10.1093\/brain\/awy255","DOI":"10.1093\/brain\/awy255"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kim H, Dill S, O'Brien M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406-8. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218690","DOI":"10.1136\/annrheumdis-2020-218690"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Le Voyer T, Gitiaux C, Authier FJ, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology (Oxford). 2021;60(12):5801-8. https:\/\/doi.org\/10.1093\/rheumatology\/keab116","DOI":"10.1093\/rheumatology\/keab116"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Zhang J, Sun L, Shi X, et al. Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China. Arthritis Res Ther. 2023;25(1):204. https:\/\/doi.org\/10.1186\/s13075-023-03170-z","DOI":"10.1186\/s13075-023-03170-z"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Wilkinson MG, Deakin CT, Papadopoulou C, et al. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J. 2021;19(1):146. https:\/\/doi.org\/10.1186\/s12969-021-00637-8","DOI":"10.1186\/s12969-021-00637-8"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Rossano M, Conti EA, Bocca P, et al. Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with JAK-inhibitors: a case report. Front Immunol. 2023;14:1288675. https:\/\/doi.org\/10.3389\/fimmu.2023.1288675","DOI":"10.3389\/fimmu.2023.1288675"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Li Y, Huang B, Andorf S, et al. Comparative effectiveness and safety of the JAK inhibitors and biologic disease-modifying antirheumatic drugs in treating children with nonsystemic juvenile idiopathic arthritis: a Bayesian meta-analysis of randomized controlled trials. ACR Open Rheumatol. 2025;7(2):e11788. https:\/\/doi.org\/10.1002\/acr2.11788","DOI":"10.1002\/acr2.11788"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Eber C, Verrier ER. Hijacking JAKis: JAK inhibitors as potential antiviral molecules, a mini review. Antiviral Res. 2025;237:106153. https:\/\/doi.org\/10.1016\/j.antiviral.2025.106153","DOI":"10.1016\/j.antiviral.2025.106153"},{"key":"ref29","unstructured":"Statens Serum Institut. Vaccinationsintervaller og tilpasning, 2024. https:\/\/www.ssi.dk\/vaccinationer\/boernevaccination\/vaccination-mod-livmoderhalskraeft\/vaccinationsintervaller-og-tilpasning (26. jun 2025)"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:17:45Z","timestamp":1758892665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V09240622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":30,"URL":"https:\/\/doi.org\/10.61409\/v09240622","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,8,11]]}}}